Trial Profile
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 24 Jun 2020 Status changed from recruiting to discontinued.
- 06 Nov 2019 Results assessing the tolerability and efficacy of Nivolumab in patients with allogeneic stem cell transplantation released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Oct 2018 Planned End Date changed from 1 Mar 2020 to 20 Mar 2022.